Our law firm is investigating the sales practices of FINRA broker-dealers who sold investments in Bre-X Minerals, Ltd. Financial advisors registered with FINRA brokerage firms may have recommended an unsuitable concentration of Bre-X investments into their client’s investment portfolios. Further, KlaymanToskes is investigating the level of due diligence performed by FINRA brokerage firms who approved the sale of Bre-X investments to their customers. Under FINRA rules, brokerage firms have an obligation to fully vet the issuer of any security, before allowing their brokers to sell securities issued by that entity. In the event brokers sold Bre-X investments without first receiving approval from their broker-dealer, this amounts to “selling away,” and the brokerage firm could be responsible for failing to properly supervise the financial advisor. Recently, FINRA arbitration claims have been filed on behalf of Bre-X investors to recover their investment losses. If you have information relevant to this investigation, contact Steven D. Toskes or Jahan K. Manasseh of KlaymanToskes, toll-free, at (888) 997-9956.
Founding Partner, KlaymanToskes
Lawrence L. Klayman
Managing and founding partner at KlaymanToskes. Former Wall Street securities broker with decades of experience representing high‑net‑worth and institutional investors nationwide. Has recovered over a quarter‑billion dollars for aggrieved investors and is frequently quoted in leading financial publications, including The Wall Street Journal, The New York Times, and Barron’s.
Covered on this page
